About 3SBIO Company

Sansheng Pharmaceutical (the “Company” or “Sansheng Pharmaceutical”, together with its subsidiaries collectively referred to as the “Group”) is a leading biotechnology company in the People's Republic of China (“China”). As a pioneer in the biotechnology industry in China, the Group has rich experience in R&D, production and marketing of biomedical products. The Group's core products include a variety of biopharmaceuticals, namely terbiopharmaceuticals, recombinant human erythropotropin (“rhEPO”) products Ibio and Cybol, Exipp and Ceptin, and the small molecule drug Mandy. Terbiao is the only commercialized recombinant human thrombocytopoietin (“rHTPO”) product in the world today. According to IQVIA1, in the first half of 2024, in terms of sales, Terbiao's share of the thrombocytopenia 2 treatment market in mainland China was 66.2%. With two rHPO products, the Group has been the leader in the RHPO market in mainland China for more than 20 years, accounting for a total market share of 42.7% in the first half of 2024. Exaipu is the first tumor necrosis factor (“TNF”) alpha inhibitor product launched in the mainland China market. Mandy also dominates the minoxidil market in mainland China. The Group is also increasing products through internal research and development (“R&D”) and a number of external strategic collaborations to expand the field of treatment. In the first half of 2024, the Group introduced simeglutide injections to actively expand the domestic weight loss market. On June 30, 2024, out of 28 products under development actively developed by the Group, 25 were developed as innovative drugs in mainland China. Among these products under development, 15 are antibodies, 7 are other biological products, and 6 are small molecule drugs. The Group has 12 products under development in hematology/oncology; 10 products under development target autoimmune diseases (including rheumatoid arthritis (“RA”)), and other diseases, including intractable gout and ophthalmic diseases (such as retinal branch vein occlusion (“BRVO”)); 4 products under development in nephrology; 1 product under dermatology research; and 1 product under metabolic research. The industries in which the Group operates are very attractive. Biotechnology is revolutionizing the pharmaceutical industry by addressing unmet pharmaceutical needs and providing innovative treatments for a wide range of human diseases. In mainland China, the biopharmaceutical industry has received strong support from the government and has been recognized as an important strategic emerging industry by the State Council of China. Strong government support and the increasing adoption of biopharmaceutical products by mainland Chinese physicians have contributed to the strong growth of the industry. The Group is expanding globally. For the six months ended June 30, 2024 (the “reporting period”), the Group's products were sold to 16 countries. In the long run, the Group aims to market its products in developed countries. The Group also cooperates with international partners to develop and market the Group's products under development, such as pegsiticase and anti-programmed death receptor 1 (“PD-1”) monoclonal antibodies (“monoclonal antibodies”). The Group aims to focus on research and development to provide innovative treatments for patients in mainland China and around the world. As of June 30, 2024, the Group had operating facilities in Shenyang, Shanghai, Hangzhou and Shenzhen (all located in mainland China) and Como, Italy, with 5,607 employees. The Group's pharmaceutical products are promoted and sold in all provinces, autonomous regions and municipalities directly under the Central Government in mainland China, as well as in certain overseas countries and regions. During the reporting period, the Group's nationwide distribution network sold the Group's products to more than 9,700 hospitals and medical institutions in mainland China.